Radiotherapy for Locally Advanced and High-Risk Skin Cancer
Skin cancer is the most common cancer that affects mankind. While most skin cancers present in an early stage and require relatively simple forms of treatment, some skin cancers are complex, locally advanced and high risk and require well-coordinated multidisciplinary management. In this educational session, we will discuss management of complex and high-risk skin cancers including locally advanced basal cell and cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. These malignancies are common in general radiation oncology practice, but independently are relatively unusual entities. A panel of specialists in complex, locally advanced and high-risk skin cancers will review epidemiology, biology, diagnosis, staging work-up and treatment by discussing several representative and educational cases.
This program is designed to meet the interest of radiation oncologists, medical oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, dosimetrists, radiation biologists and radiation oncology residents.
- Recognize and describe multidisciplinary care available to improve skin cancer patient outcomes.
- Summarize best skin cancer management practices and put them into use to assist in improving patient care.
- Christopher Barker, MD has no disclosures to declare.
- Sue Yom, MD, PhD recieveds compensation.funding from Genentech,ASTRO,UpToDate,Merck,Bristol-Myers-Squibb and Clinigen.
- B. Ashleigh Guadagnolo, MD, PhD has no disclosures to declare.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.